Evidence map›Paper›PMID 39233019›Full record

ArticleAmerican journal of ophthalmology2025

Targeting the Tie-2 Receptor With Faricimab in Central Serous Chorioretinopathy: A Case Series Motivated by a Genetic Finding.

Joel T Rämö, Leo A Kim, Tomasz Stryjewski, Priya P Shah, Romy Bejjani, Frank L Brodie, Dean Eliott, Lucia Sobrin, Demetrios G Vavvas, Elizabeth J Rossin

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Efficacy and safety of intravitreal faricimab for choroidal neovascularization secondary to central serous chorioretinopathy - a multicentre study.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Joel T RämöFrom the Broad Institute of MIT and Harvard (J.T.R., E.J.R.), Cambridge, Massachusetts, USA; Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE) (J.T.R.), University of Helsinki, Helsinki, Finland; Massachusetts Eye and Ear (J.T.R., D.E., L.S., D.G.V., E.J.R.), Boston, Massachusetts, USA.
Leo A KimDepartment of Ophthalmology (L.A.K., P.P.S., R.B., D.E., L.S., D.G.V., E.J.R.), Harvard Medical School, Massachusetts Eye and Ear, Boston, Massachusetts, USA.
Tomasz StryjewskiTallman Eye Associates (T.S.), Lawrence, Massachusetts, USA.
Priya P ShahDepartment of Ophthalmology (L.A.K., P.P.S., R.B., D.E., L.S., D.G.V., E.J.R.), Harvard Medical School, Massachusetts Eye and Ear, Boston, Massachusetts, USA.
Romy BejjaniDepartment of Ophthalmology (L.A.K., P.P.S., R.B., D.E., L.S., D.G.V., E.J.R.), Harvard Medical School, Massachusetts Eye and Ear, Boston, Massachusetts, USA.
Frank L BrodieDepartment of Ophthalmology (F.L.B), University of San Francisco California, San Francisco, California, USA.
Dean EliottMassachusetts Eye and Ear (J.T.R., D.E., L.S., D.G.V., E.J.R.), Boston, Massachusetts, USA; Department of Ophthalmology (L.A.K., P.P.S., R.B., D.E., L.S., D.G.V., E.J.R.), Harvard Medical School, Massachusetts Eye and Ear, Boston, Massachusetts, USA.
Lucia SobrinMassachusetts Eye and Ear (J.T.R., D.E., L.S., D.G.V., E.J.R.), Boston, Massachusetts, USA; Department of Ophthalmology (L.A.K., P.P.S., R.B., D.E., L.S., D.G.V., E.J.R.), Harvard Medical School, Massachusetts Eye and Ear, Boston, Massachusetts, USA.
Demetrios G VavvasMassachusetts Eye and Ear (J.T.R., D.E., L.S., D.G.V., E.J.R.), Boston, Massachusetts, USA; Department of Ophthalmology (L.A.K., P.P.S., R.B., D.E., L.S., D.G.V., E.J.R.), Harvard Medical School, Massachusetts Eye and Ear, Boston, Massachusetts, USA.
Elizabeth J RossinFrom the Broad Institute of MIT and Harvard (J.T.R., E.J.R.), Cambridge, Massachusetts, USA; Massachusetts Eye and Ear (J.T.R., D.E., L.S., D.G.V., E.J.R.), Boston, Massachusetts, USA; Department of Ophthalmology (L.A.K., P.P.S., R.B., D.E., L.S., D.G.V., E.J.R.), Harvard Medical School, Massachusetts Eye and Ear, Boston, Massachusetts, USA. Electronic address: Elizabeth_rossin@meei.harvard.edu.

Funding

Mass Eye and Ear-Vision Clinical Scientist Development ProgramK12EY016335 · NEI · MASSACHUSETTS EYE AND EAR INFIRMARY · PI Reza Dana · 2004 to 2026
$12.3M
Genetics of central serous chorioretinopathy and choroidal thickeningK23EY035342 · NEI · MASSACHUSETTS EYE AND EAR INFIRMARY · PI Elizabeth Jeffries Rossin · 2024 to 2026
$831k
NEI NIH HHS K12 EY016335NEI NIH HHS K23 EY035342
6 · The paper itself

Abstract

purposeTo investigate the effects of faricimab, a bispecific antibody targeting VEGF and Ang-2 (thus increasing Tie-2 activity), in patients with CSC based on a recent genetic study that implicated Tie-2 signaling in CSC pathophysiology.

designA retrospective interventional multicenter case series.

methodsWe included patients with chronic CSC (persistent or recurrent SRF for ≥6 months) who received at least one faricimab 6 mg injection between January 1 2022, and April 1 2024,. Study sites included Massachusetts Eye and Ear and University of California San Francisco. Patients with evidence of a choroidal neovascular membrane on color photos, optical coherence tomography (OCT) and/or fluorescein angiography were excluded. 16 eyes (15 patients) met the inclusion criteria. The median central macular thickness at each visit from 52 weeks before to 52 weeks after the first faricimab injection was calculated using automated Heidelberg Spectralis ETDRS subfield measurements.

resultsPrior to treatment with faricimab, CSC had been diagnosed a median of 4.1 years (range 0.9-8) earlier and SRF (and intraretinal fluid [IRF] in a subset) had been continuously present for a median of 30 weeks (range 9-257). Decreases in macular thickness were observed in 14/16 eyes after the first faricimab injection and in 14/16 eyes in the full follow-up period compared with prior, 10 of which experienced complete resolution of SRF following the start of the first series of injections at a median of 4 weeks (range 2-25). One eye worsened after the second injection. The median improvement in macular thickness was 40 μm [range -3 to 89.5] (P = .0007). Upon review of OCT images, reductions in macular thickness were consistent with reductions in SRF and/or IRF. Visual acuity improved by 2 lines or more in 6/16 eyes.

conclusionsIn a retrospective case series of patients with chronic CSC and longstanding SRF, we observed improvement in macular thickness after intravitreal faricimab. While the small number of patients and variable natural history of CSC preclude definitive conclusions, a randomized controlled trial seems warranted.

Indexed as

Central Serous ChorioretinopathyFluorescein AngiographyIntravitreal InjectionsReceptor, TIE-2Tomography, Optical CoherenceVisual AcuityAdultAgedAntibodies, BispecificFemaleHumansMaleMiddle AgedRetrospective StudiesVascular Endothelial Growth Factor AAntibodies, BispecificReceptor, TIE-2TEK protein, humanVascular Endothelial Growth Factor AVEGFA protein, human

Identifiers

PMID39233019
PMCPMC11968134

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.